2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T5b3,Hepatitis C virus (HCV) infection is a major public health problem despite the availability of highly effective and curative direct acting antiviral (DAA) treatments. Low diagnostic rates, driven in part by a two-step diagnostic process and the need for molecular confirmation, pose a significant barrier to timely treatment. Here we describe the development, analytical characterization, and a preliminary clinical validation study of a rapid, user-friendly, sensitive, qualitative molecular test for point-of-care HCV testing. This study evaluated the analytical performance of a 15-minute time to result qualitative molecular test for HCV on the sample-to-answer point-of-care DASH® Rapid PCR System. The dynamic range, limit of detection, analytical specificity, and the equivalent detection of genotypes 1-6 were assessed. A small clinical validation study was independently conducted by Johns Hopkins investigators using retrospectively collected specimens. The Research Use Only (RUO) DASH® HCV assay has wide dynamic range, can detect HCV genotypes 1-6, and has a detection limit of 200 IU/mL with 100 μL specimen volume addition. In a preliminary study of 97 plasma specimens, the DASH® HCV assay demonstrated 100% positive percent agreement (PPA) and 100% negative percent agreement (NPA) when compared to commercial platforms. The DASH® HCV test holds potential to enable same-day diagnosis and treatment in support of HCV elimination efforts.31:T821,Abstract Background Hepatitis C virus (HCV) infection is a major public health problem despite the availability of highly effective and curative direct-acting antiviral treatments. Low diagnostic rates, driven in part by a 2-step diagnostic process and the need for molecular confirmation, pose a significant barrier to timely treatment. Here we describe the development, analytical characterization, and a preliminary clinical validation study of a rapid, user-friendly, sensitive, qualitative molecular test for point-of-care HCV testing. Methods This study evaluated the analytical performance of a 15-minute time to result qualitative molecular test for HCV on the sample-to-answer point-of-care DASH Rapid PCR System. The dynamic range, limit of detection, analytical specificity, and the equivalent detection of genotypes 1–6 were assessed. A small clinical validation study was independently conducted by Johns Hopkins University investigators using retrospectively collected specimens. Results The Research Use Only DASH HCV assay has wide dynamic range, can detect HCV genotypes 1–6, and has a detection limit of 200 IU/mL with 100 μL specimen volume addition. In a preliminary study of 97 plasma specimens, the DASH HCV assay demonstrated 100% positive percent agreement and 100% negative percent agreement when compared to commercial platforms. Conclusions The DASH HCV test holds potential to enable same-day diagnosis and treatment in support of HCV elimination efforts. 32:T6e6,Hepatocellular carcinoma (HCC) incidence is on the rise. While biological factors have been studied extensively, how Mental Health Diseases (MHD) affect the risk of HCC remains unexplored. In this study, we aimed to determine whether MHD are associated with HCC incidence among at-risk Veterans. We conducted a retrospective cohort study of Veterans with cirrhosis (2000-2021). MHD were defined by ICDs and mental health surveys and were categorized into individual MHDs or, alcohol/substance use disorders (AUD/SUD), non-AUD/SUD (anxiety, depression, PTSD, schizophrenia and bipolar), and any MHD, based on clinical relevance and correlations (>0.7). Cirrhosis was defined by 2-consecutives FIB-4>3.25 or validated ICDs. The Census Bureau and RUCAC geospatial codes were used to define rurality. The association between incident HCC, MHD, rurality and HCV (per direct acting antiviral-DAA-era) was analyzed using multivariable Cox logistic regression. We identified 221,721 Veterans, 7% (n=15,710) of whom developed HCC. AUD/SUD was the most prevalent MHD (n=44,140; 19.6%). AUD (6.74%) was the most common individual MHD, with large overlaps between MHD. DAAs improved but did not eliminate the risk of HCC in Veterans (adj.HR=1.32, 95%CI 1.26-1.38 vs. adj.HR=1.59, 95%CI1.89-2.14). AUD/SUD was a significant risk for HCC in the pre-DAA era (adj.HR=1.42, 95%CI1.28-1.59). In the post-DAA era, AUD/SUD significantly interacted with HCV (adj.HR=1.98, 95%CI1.54-2.55). In a large cohort of Veterans with cirrhosis, any MHD significantly increased incident HCC risk and associated with active HCV, even in the post-DAA era, with AUD and ALD having the largest effects. Multidisciplinary management of vulnerable, at-risk Veterans is needed to mitigate the risk of HCC.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Hepatitis C: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Hepatitis C (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Hepatitis%20C\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Hepatitis C\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Hepatitis%20C\"}]}}"}}]],["$","$L2f",null,{"title":"Hepatitis C: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Hepatitis C with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1097/hc9.0000000000000979","pmid":"42530302","title":"High incidence of advanced liver disease and mortality in patients presenting with alcohol use disorder","journal_title":"Hepatology Communications","journal_issn":"2471-254X","published_at":"2026-08-01T00:00:00.000Z","url":"https://doi.org/10.1097/hc9.0000000000000979","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-06T13:22:09.028Z","updated_at":"2026-08-06T13:22:09.028Z","tags":[{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"condition","value":"Alcohol-Associated Liver Disease","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"condition","value":"Alcohol Use Disorder","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"condition","value":"Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"condition","value":"Liver Cirrhosis","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"generic","value":"FIB-4 index","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"modality","value":"Non-Invasive Fibrosis Assessment","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"sample_size","value":"n=32808","value_numeric":32808},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"warning","value":"Abstinence and relapse data were unavailable, making it impossible to attribute outcomes specifically to continued vs. discontinued alcohol use.","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"warning","value":"Hepatitis C was captured at any time during follow-up (not only at baseline), which may slightly overestimate its prevalence as a baseline comorbidity.","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"warning","value":"The FIB-4 'modality' and 'generic' tags are used here for a diagnostic scoring tool rather than a drug — this is an unconventional use of those tag types, but no more specific tag type exists for diagnostic indices.","value_numeric":null},{"paper_doi":"10.1097/hc9.0000000000000979","tag_type":"warning","value":"The study population is drawn from a single large US health system (UPMC); generalizability to uninsured or non-academic populations may be limited.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study followed 32,808 adults with AUD (no pre-existing cirrhosis) presenting to UPMC healthcare centers between 2006–2017, tracking incident cirrhosis and all-cause mortality over an average of 5.7 years (through August 2021).","key_result":"12.3% developed incident cirrhosis and 20.2% died during follow-up. Key risk factors for cirrhosis: hepatitis C (HR 3.15), diabetes mellitus (HR 1.52); African American race was protective (HR 0.76). Developing cirrhosis more than doubled mortality (HR 2.55). Patients with all 3 risk factors (White race, DM, hepatitis C) had ~38% cirrhosis incidence at 5 years vs. ~6% in those with none.","limitations":"- No data on alcohol abstinence or relapse during follow-up, limiting outcome interpretation.\n- Relies on ICD codes; compensated cirrhosis likely underestimated due to its asymptomatic nature.\n- Single health system (UPMC); patients seeking care outside the network may be missed.","practice_takeaway":"Screen all AUD patients for liver disease at presentation, and prioritize those with diabetes or hepatitis C for closer surveillance — they carry the highest risk of cirrhosis and death. FIB-4 alone has poor sensitivity (37%) for early ALD detection in AUD; clinical risk factors (race, DM, hepatitis C) are more useful for stratification."}},{"doi":"10.1002/jia2.70183","pmid":"42517660","title":"Reimagining Hepatitis C Elimination: Time for Actions, Not Targets","journal_title":"Journal of the International AIDS Society","journal_issn":"1758-2652","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1002/jia2.70183","source_score":9,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:17:43.671Z","updated_at":"2026-08-04T18:17:43.671Z","tags":[{"paper_doi":"10.1002/jia2.70183","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"generic","value":"daclatasvir","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"generic","value":"ravidasvir","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"generic","value":"sofosbuvir","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"generic","value":"sofosbuvir/velpatasvir","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"modality","value":"Direct-Acting Antiviral","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"modality","value":"Needle and Syringe Programme","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"modality","value":"Opioid Agonist Therapy","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"study_design","value":"Viewpoint / Expert Commentary","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"warning","value":"Some cited references (e.g., WHO Global Hepatitis Report 2026) are very recent and may not yet be widely accessible; data figures should be verified against primary sources.","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the authors' call to redirect global HCV strategy, not a finding from a clinical trial.","value_numeric":null},{"paper_doi":"10.1002/jia2.70183","tag_type":"warning","value":"This is an expert viewpoint, not a primary research study; evidence levels for individual recommendations vary and are drawn from cited literature rather than new data.","value_numeric":null}],"summaries":{"what_studied":"This viewpoint evaluates the global shortfall in achieving WHO 2030 HCV elimination targets and proposes four concrete action steps — prevention (OAT/PNSPs), testing (point-of-care campaigns), treatment (affordable pan-genotypic regimens), and follow-up (reinfection monitoring) — to redirect efforts beyond aspirational targets.","key_result":"As of 2024, only 13 countries are on track to meet WHO HCV elimination targets; 0.9 million people newly acquired HCV (only 8% decline from 2015), 64% of infected individuals remain undiagnosed globally, and HCV-related deaths remain at 240,000 (only 12% reduction from 2015).","limitations":"This is an expert viewpoint without primary data; recommendations rely on cited evidence but are not based on a systematic review or meta-analysis. Large data gaps in country-level HCV surveillance are acknowledged by the authors.","practice_takeaway":"Clinicians treating PWID should prioritize OAT and advocate for prison needle/syringe access, use point-of-care RNA testing for immediate test-and-treat, and offer at least biannual HCV RNA retesting in the first few years post-cure for high-risk patients. Generic sofosbuvir/daclatasvir at $60 USD/12-week course is available in 105 LMICs through CHAI/Hepatitis Fund agreements."}},{"doi":"10.1016/s2468-1253(26)00220-7","pmid":"42508445","title":"WHO global hepatitis report 2026: guiding global action for elimination","journal_title":"The Lancet Gastroenterology & Hepatology","journal_issn":"2468-1253","published_at":"2026-07-27T00:00:00.000Z","url":"https://doi.org/10.1016/s2468-1253(26)00220-7","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:36:58.790Z","updated_at":"2026-07-31T13:36:58.790Z","tags":[{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"condition","value":"Hepatitis B","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"condition","value":"Viral Hepatitis","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"modality","value":"Antiviral Therapy","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"modality","value":"Vaccination","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"study_design","value":"Global Health Report / Surveillance","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"warning","value":"Level of evidence set to 7 (expert opinion / narrative report) given the nature of a WHO global report.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"warning","value":"Study design tag 'Global Health Report / Surveillance' is non-standard; this document is a WHO policy/epidemiological report, not a clinical trial or observational study.","value_numeric":null},{"paper_doi":"10.1016/s2468-1253(26)00220-7","tag_type":"warning","value":"The source text provides only the paper title, DOI, journal, and publication date — no abstract or full text was supplied. All structured content is inferred from the title and known context of WHO hepatitis elimination reports. Specific statistics, country data, and outcome numbers are not verifiable from the provided text.","value_numeric":null}],"summaries":{"what_studied":"The WHO Global Hepatitis Report 2026 evaluates the current state of viral hepatitis elimination progress worldwide, assessing coverage of prevention, testing, and treatment interventions against WHO 2030 targets.","key_result":"The report provides updated global epidemiological data and tracks country-level progress toward hepatitis B and C elimination targets, identifying gaps in testing, treatment, and vaccination coverage that must be closed by 2030.","limitations":"The report is a global policy and surveillance document rather than a primary research study; country-level data quality and completeness vary significantly, which may affect the reliability of global estimates.","practice_takeaway":"Clinicians and health systems should use this report's benchmarks to identify local gaps in hepatitis B vaccination, HBV/HCV testing, and treatment scale-up. Prioritizing linkage to care for diagnosed but untreated patients remains critical to meeting 2030 elimination goals."}},{"doi":"10.1136/sextrans-2026-056936","pmid":"42236159","title":"Low HCV seroprevalence among PLWH: a large cross-sectional study of 6722 individuals","journal_title":"Sexually Transmitted Infections","journal_issn":"1368-4973","published_at":"2026-06-03T00:00:00.000Z","url":"https://doi.org/10.1136/sextrans-2026-056936","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:22.430Z","updated_at":"2026-06-10T14:24:22.430Z","tags":[{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"condition","value":"HIV Infection","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"modality","value":"Serologic Screening","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"sample_size","value":"n=6722","value_numeric":6722},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"warning","value":"Genotyping data were available for only 8 of 24 seropositive PLWH; genotype distribution should be interpreted cautiously.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"warning","value":"No transmission route or injection drug use data were reported, which limits risk stratification.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"warning","value":"The OR of 1.85 approached but did not reach significance (95% CI crosses 1.0), so the clinical relevance of any elevated risk remains uncertain.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056936","tag_type":"warning","value":"The study is restricted to Istanbul and may not generalize to rural Türkiye or other regions with different HCV epidemiology.","value_numeric":null}],"summaries":{"what_studied":"HCV seroprevalence was measured in 3,361 PLWH and 3,361 age- and sex-matched HIV-negative controls across nine hospitals in Istanbul, Türkiye (January 2022–October 2025), with age-group trend analysis and limited genotyping in PLWH.","key_result":"HCV seroprevalence was 0.71% in PLWH (24/3,361) vs. 0.39% in controls (13/3,361); the difference was not significant (OR 1.85; 95% CI 0.94–3.70; p=0.098). Seropositivity rose sharply with age (p<0.001), with zero cases under 30 years. Among 8 genotyped PLWH, genotype 3 predominated (62.5%).","limitations":"- Genotyping was available for only 8 of 24 seropositive PLWH, limiting conclusions about circulating strains.\n- Retrospective data from a single city (Istanbul) may not represent all of Türkiye or other low-endemic settings.\n- Transmission route and injection drug use history were not reported, preventing risk-factor analysis.","practice_takeaway":"In low-endemic settings like Türkiye, routine universal HCV screening of PLWH may have limited yield; an age-based approach targeting older patients (especially those over 50–70) may be more efficient. Clinicians should still confirm local epidemiology before adjusting screening protocols."}},{"doi":"10.1007/s10508-026-03455-9","pmid":"42236635","title":"High-Risk Sexual Contacts in Nepal and India Among Male Labor Migrants: Findings from the 2024 National Survey in Nepal","journal_title":"Archives of Sexual Behavior","journal_issn":"0004-0002","published_at":"2026-06-03T00:00:00.000Z","url":"https://doi.org/10.1007/s10508-026-03455-9","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-15T13:21:48.513Z","updated_at":"2026-06-15T13:21:48.513Z","tags":[{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"category","value":"Psychology, Clinical","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"condition","value":"HIV Infection","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"condition","value":"Sexually Transmitted Infections","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"condition","value":"Syphilis","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"modality","value":"Behavioral Intervention","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"modality","value":"Condom Promotion","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"modality","value":"HIV Testing","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"sample_size","value":"n=1872","value_numeric":1872},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"study_design","value":"Cross-Sectional Survey","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"warning","value":"Study design is cross-sectional with self-reported behavioral outcomes; causality and generalizability are limited.","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"warning","value":"Syphilis prevalence (2.1%) and HCV prevalence (38.4%) are based on subgroups only (symptomatic men and ever-injectors, respectively), not the full sample — these figures should not be interpreted as population-level estimates for all male labor migrants.","value_numeric":null},{"paper_doi":"10.1007/s10508-026-03455-9","tag_type":"warning","value":"The DOI publication year in the URL (03455-9) and article date (2026) are consistent, but the 'Received' date is listed as July 2025, suggesting a relatively short peer-review cycle; full text was not available for review.","value_numeric":null}],"summaries":{"what_studied":"A 2024 national HIV bio-behavioral survey of 1,872 male labor migrants (MLM) across all 7 provinces of Nepal evaluated risky sexual behaviors — including sex with female sex workers (FSW) — plus HIV, syphilis, and HCV prevalence using household-level multi-stage cluster sampling in 14 high-migration districts.","key_result":"6.6% of MLM reported sex with an FSW in the past 12 months (range: 1.1% in Lumbini to 10.3% in Sudurpaschim); condom use at last FSW contact was 63.9% in Nepal vs. 93.8% in India. HIV prevalence was 0.2%, syphilis prevalence among symptomatic men was 2.1%, and HCV prevalence was 38.4% among those who had ever injected drugs.","limitations":"- Syphilis and HCV testing were restricted to symptomatic/high-risk subgroups, so prevalence estimates are not population-representative.\n- Self-reported sexual behavior data are subject to social desirability bias, likely underestimating FSW contact rates.\n- Sampling was limited to 14 districts with highest migration density; findings may not generalize to all Nepali labor migrants.","practice_takeaway":"Clinicians and public health programs working with Nepali male labor migrants should prioritize condom promotion — especially within Nepal, where use at FSW contact (63.9%) lags far behind India (93.8%). HIV testing, STI screening, and harm reduction for people who inject drugs should be integrated into migrant health services, with particular focus on Sudurpaschim and Karnali provinces where FSW contact rates are highest."}},{"doi":"10.1136/gutjnl-2025-337838","pmid":"42135055","title":"Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis","journal_title":"Gut","journal_issn":"0017-5749","published_at":"2026-05-14T00:00:00.000Z","url":"https://doi.org/10.1136/gutjnl-2025-337838","source_score":13,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-22T13:22:27.210Z","updated_at":"2026-05-22T13:22:27.210Z","tags":[{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"condition","value":"Alcohol-Related Liver Disease","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"condition","value":"Hepatitis B","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"condition","value":"Metabolic Dysfunction-Associated Steatotic Liver Disease","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"modality","value":"Antiviral Therapy","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"modality","value":"Vaccination","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"sample_size","value":"n=857","value_numeric":857},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"warning","value":"'Practice-changing' impact flag applied because this is the most comprehensive updated global estimate to date, directly informing WHO hepatitis elimination targets.","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"warning","value":"Sample size tag reflects number of eligible publications (n=857), not individual patients — total patient count is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1136/gutjnl-2025-337838","tag_type":"warning","value":"Study period ends December 2023; HCC incidence figures are projected to 2022 using external incidence data and may not reflect the most recent epidemiological trends.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and meta-analysis estimating the fraction of hepatocellular carcinoma (HCC) attributable to HBV, HCV, alcohol, and metabolic dysfunction-associated steatotic liver disease (MASLD) by country, region, and globally, using studies published between October 2014 and December 2023 with ≥20 HCC patients reporting both HBV and HCV prevalence.","key_result":"Globally, HBV and HCV together account for ~73% of HCC burden: HBV attributable fraction (AF) = 52% (~345,434 cases in 2022); HCV AF = 21% (~134,418 cases in 2022). HBV AF peaked in Eastern Asia (70%) and was lowest in Northern Europe (6%); HCV AF was highest in Northern Africa (77%). Alcohol and/or MASLD contributed >30% of HCC in parts of Europe and South America.","limitations":"Pooled estimates rely on prevalence data from HCC case series, which may not be nationally representative. Study quality and case ascertainment methods varied across 81 countries. Data from some regions may be sparse, limiting precision of regional estimates.","practice_takeaway":"HBV vaccination and antiviral therapy targeting HBV remain the highest-yield global interventions, especially in Eastern Asia and sub-Saharan Africa, while HCV treatment scale-up is most urgent in Northern Africa and Egypt. Clinicians in Europe and South America should also screen for alcohol use and MASLD as major competing HCC risk factors."}},{"doi":"10.1016/j.ajt.2026.03.022","pmid":"41903854","title":"Hepatitis C virus-positive pancreas donors: A safe strategy to reduce transplant wait times","journal_title":"American Journal of Transplantation","journal_issn":"1600-6135","published_at":"2026-03-27T00:00:00.000Z","url":"https://doi.org/10.1016/j.ajt.2026.03.022","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-06T13:36:13.820Z","updated_at":"2026-07-06T13:36:13.820Z","tags":[{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"condition","value":"Pancreas Transplantation","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"modality","value":"Solid Organ Transplantation","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"warning","value":"Only metadata (title, DOI, journal, publication date) was provided — no abstract, methods, results, or full text were included. Key details such as sample size, study design, specific outcomes, and comparator groups could not be extracted. Summary fields reflect reasonable inferences from the title only and should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"warning","value":"Study design tag ('Cohort Study') and level of evidence ('3') are inferred from context; the actual design is not confirmed from the source text.","value_numeric":null},{"paper_doi":"10.1016/j.ajt.2026.03.022","tag_type":"warning","value":"The impact_flag 'practice_changing' is tentative, based solely on the paper's title framing; the actual findings could not be verified.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated the safety and outcomes of using hepatitis C virus (HCV)-positive pancreas donors for transplantation as a strategy to reduce wait times for pancreas transplant candidates.","key_result":"The use of HCV-positive pancreas donors was associated with acceptable transplant outcomes, supporting this as a viable strategy to expand the donor pool and decrease wait times, though specific outcome numbers are not available from the provided abstract.","limitations":"Full study details and outcome data are not available from the provided source text alone; generalizability may be limited by center-specific protocols and the evolving availability of direct-acting antiviral (DAA) therapy post-transplant.","practice_takeaway":"Transplant programs may consider HCV-positive pancreas donors as a safe option to expand the donor pool. Patients on the pancreas transplant waitlist should be counseled about this option, given the availability of highly effective DAA therapy for post-transplant HCV treatment."}},{"doi":"10.1093/infdis/jiaf608","pmid":"41369203","title":"Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH Rapid Polymerase Chain Reaction System","journal_title":"The Journal of Infectious Diseases","journal_issn":"0022-1899","published_at":"2025-12-10T00:00:00.000Z","url":"https://doi.org/10.1093/infdis/jiaf608","source_score":424,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-15","doi":"10.1093/infdis/jiaf608","days":"30","issn":"0022-1899","rank":"1","field":"Clinical Medicine","score":"424","category":"Immunology","categories":["Immunology","Infectious Diseases"],"_categories":["Immunology","Infectious Diseases"]},"pubmed":{"doi":"10.1093/infdis/jiaf608","title":"Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH® Rapid PCR System.","journal":"The Journal of infectious diseases","methods":"","results":"The Research Use Only (RUO) DASH® HCV assay has wide dynamic range, can detect HCV genotypes 1-6, and has a detection limit of 200 IU/mL with 100 μL specimen volume addition. In a preliminary study of 97 plasma specimens, the DASH® HCV assay demonstrated 100% positive percent agreement (PPA) and 100% negative percent agreement (NPA) when compared to commercial platforms.","abstract":"$30","keywords":["Diagnosis","Hepatitis C","Point-of-Care","Rapid"],"pubmed_id":"41369203","conclusions":"","publication_date":"2025-12-10T00:00:00"},"crossref":{"DOI":"10.1093/infdis/jiaf608","URL":"https://doi.org/10.1093/infdis/jiaf608","ISSN":["0022-1899","1537-6613"],"link":[{"URL":"https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaf608/65818740/jiaf608.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaf608/65818740/jiaf608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH Rapid Polymerase Chain Reaction System"],"author":[{"given":"Jennifer L","family":"Reed","sequence":"first","affiliation":[{"name":"Center for Innovation in Global Health Technologies, Robert J. Havey Institute for Global Health, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,"},{"name":"Department of Biomedical Engineering, Northwestern University , Evanston, Illinois ,"}]},{"given":"Matthew A","family":"Butzler","sequence":"additional","affiliation":[{"name":"Center for Innovation in Global Health Technologies, Robert J. Havey Institute for Global Health, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,"},{"name":"Department of Biomedical Engineering, Northwestern University , Evanston, Illinois ,"}]},{"given":"Claudia A","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Center for Global Communicable and Emerging Infectious Diseases, Robert J. Havey Institute for Global Health, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,"}]},{"given":"Yukari C","family":"Manabe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,"}]},{"given":"Jeffrey","family":"Holden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,"}]},{"given":"David L","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,"}]},{"given":"Andrea L","family":"Cox","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,"}]},{"given":"Sally M","family":"McFall","sequence":"additional","affiliation":[{"name":"Center for Innovation in Global Health Technologies, Robert J. Havey Institute for Global Health, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,"},{"name":"Department of Biomedical Engineering, Northwestern University , Evanston, Illinois ,"}]}],"funder":[{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000002","id-type":"DOI","asserted-by":"crossref"}],"DOI":"10.13039/100000002","name":"National Institutes of Health","award":["1U01CA292771"],"award-info":[{"award-number":["1U01CA292771"]}],"doi-asserted-by":"crossref"},{"name":"National Institute of Biomedical Engineering"},{"id":[{"id":"10.13039/100000002","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000002","name":"NIH","award":["U54 EB027049"],"award-info":[{"award-number":["U54 EB027049"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000002","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000002","name":"NIH","award":["U54EB007958"],"award-info":[{"award-number":["U54EB007958"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000060","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12,10]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2025-12-03T13:19:28Z","timestamp":1764767968000,"date-parts":[[2025,12,3]]},"indexed":{"date-time":"2025-12-18T04:35:43Z","timestamp":1766032543054,"date-parts":[[2025,12,18]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000,"date-parts":[[2025,12,10]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaf608/8374811"}},"subtitle":[],"deposited":{"date-time":"2025-12-18T04:32:03Z","timestamp":1766032323000,"date-parts":[[2025,12,18]]},"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"published":{"date-parts":[[2025,12,10]]},"publisher":"Oxford University Press (OUP)","reference":[{"DOI":"10.1086/423943","key":"2025121723315208800_jiaf608-B1","year":"2004","issue":null,"author":"Jauncey","volume":"190","first-page":"1270","unstructured":null,"article-title":"Clearance of hepatitis C virus after newly acquired infection in injection drug users","journal-title":"J Infect Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025121723315208800_jiaf608-B2","year":null,"issue":null,"author":"World Health Organization","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2025121723315208800_jiaf608-B3","year":"2016","issue":null,"author":"Easterbrook","volume":"18","first-page":"3","unstructured":null,"article-title":"HIV and hepatitis testing: global progress, challenges, and future directions","journal-title":"AIDS Rev","doi-asserted-by":null},{"DOI":"10.4254/wjh.v10.i2.186","key":"2025121723315208800_jiaf608-B4","year":"2018","issue":null,"author":"Morozov","volume":"10","first-page":"186","unstructured":null,"article-title":"Hepatitis C virus: morphogenesis, infection and therapy","journal-title":"World J Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0224751","key":"2025121723315208800_jiaf608-B5","year":"2019","issue":null,"author":"Mücke","volume":"14","first-page":"e0224751","unstructured":null,"article-title":"Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(22)00346-6","key":"2025121723315208800_jiaf608-B6","year":"2023","issue":null,"author":"Trickey","volume":"8","first-page":"253","unstructured":null,"article-title":"Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025121723315208800_jiaf608-B7","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2025121723315208800_jiaf608-B8","year":"2022","issue":null,"author":"World Health Organization.","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2025121723315208800_jiaf608-B9","year":null,"issue":null,"author":"World Health Organization.","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1093/infdis/jiac049","key":"2025121723315208800_jiaf608-B10","year":"2022","issue":null,"author":"Catlett","volume":"226","first-page":"1005","unstructured":null,"article-title":"Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of hepatitis C virus RNA: a systematic review","journal-title":"J Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(17)30075-4","key":"2025121723315208800_jiaf608-B11","year":"2017","issue":null,"author":"Grebely","volume":"2","first-page":"514","unstructured":null,"article-title":"Evaluation of the Xpert HCV viral load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/jiy114","key":"2025121723315208800_jiaf608-B12","year":"2018","issue":null,"author":"Lamoury","volume":"217","first-page":"1889","unstructured":null,"article-title":"Evaluation of the Xpert HCV viral load finger-stick point-of-care assay","journal-title":"J Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.3390/diagnostics12051255","key":"2025121723315208800_jiaf608-B13","year":"2022","issue":null,"author":"Tang","volume":"12","first-page":"1255","unstructured":null,"article-title":"Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systematic review and meta-analysis","journal-title":"Diagnostics (Basel)","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12879-017-2770-5","key":"2025121723315208800_jiaf608-B14","year":"2017","issue":null,"author":"Ivanova Reipold","volume":"17","first-page":"707","unstructured":null,"article-title":"Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile","journal-title":"BMC Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jviromet.2017.06.016","key":"2025121723315208800_jiaf608-B15","year":"2017","issue":null,"author":"Neto","volume":"248","first-page":"107","unstructured":null,"article-title":"Immiscible phase filter extraction and equivalent amplification of genotypes 1–6 of hepatitis C RNA: the building blocks for point-of-care diagnosis","journal-title":"J Virol Methods","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0229424","key":"2025121723315208800_jiaf608-B16","year":"2020","issue":null,"author":"Jagodzinski","volume":"15","first-page":"e0229424","unstructured":null,"article-title":"Performance evaluation of a laboratory developed PCR test for quantitation of HIV-2 viral RNA","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1373/clinchem.2011.162958","key":"2025121723315208800_jiaf608-B17","year":"2011","issue":null,"author":"Bustin","volume":"57","first-page":"919","unstructured":null,"article-title":"Primer sequence disclosure: a clarification of the MIQE guidelines","journal-title":"Clin Chem","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.tube.2016.09.002","key":"2025121723315208800_jiaf608-B18","year":"2016","issue":null,"author":"Reed","volume":"101","first-page":"114","unstructured":null,"article-title":"Highly sensitive sequence specific qPCR detection of Mycobacterium tuberculosis complex in respiratory specimens","journal-title":"Tuberculosis (Edinb)","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025121723315208800_jiaf608-B19","year":"2025","issue":null,"author":"McFall","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.diagmicrobio.2023.116120","key":"2025121723315208800_jiaf608-B20","year":"2023","issue":null,"author":"Butzler","volume":"108","first-page":"116120","unstructured":null,"article-title":"Evaluation of the analytical performance of the 15-minute point-of-care DASH SARS-CoV-2 RT-qPCR test","journal-title":"Diagn Microbiol Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.06723-11","key":"2025121723315208800_jiaf608-B21","year":"2012","issue":null,"author":"LaRue","volume":"50","first-page":"1769","unstructured":null,"article-title":"Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1086/428578","key":"2025121723315208800_jiaf608-B22","year":"2005","issue":null,"author":"Cox","volume":"40","first-page":"951","unstructured":null,"article-title":"Prospective evaluation of community-acquired acute-phase hepatitis C virus infection","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0076-6879(06)10019-1","key":"2025121723315208800_jiaf608-B23","year":"2006","issue":null,"author":"Lutfalla","volume":"410","first-page":"386","unstructured":null,"article-title":"Performing quantitative reverse-transcribed polymerase chain reaction experiments","journal-title":"Methods Enzymol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2019.02.011","key":"2025121723315208800_jiaf608-B24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Freiman JM, Wang J, Easterbrook PJ, et al Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset. J Hepatol 2019; 71:62–70.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/jiad463","key":"2025121723315208800_jiaf608-B25","year":"2024","issue":null,"author":"Ivanova Reipold","volume":"229","first-page":"S342","unstructured":null,"article-title":"Molecular point-of-care testing for hepatitis C: available technologies, pipeline, and promising future directions","journal-title":"J Infect Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025121723315208800_jiaf608-B26","year":null,"issue":null,"author":"World Health Organization.","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jvh.13672","key":"2025121723315208800_jiaf608-B27","year":"2022","issue":null,"author":"Morgan","volume":"29","first-page":"474","unstructured":null,"article-title":"Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: evidence from a global data set","journal-title":"J Viral Hepat","doi-asserted-by":"crossref"}],"short-title":[],"article-number":"jiaf608","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["The Journal of Infectious Diseases"],"reference-count":27,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,10]]},"references-count":27,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/infdis/jiaf608","is_oa":true,"title":"Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH Rapid Polymerase Chain Reaction System","updated":"2025-12-30T00:50:24+00:00","published_date":"2025-12-03","best_oa_location":{"url":"https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaf608/65818740/jiaf608.pdf","pmh_id":null,"url_for_pdf":"https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaf608/65818740/jiaf608.pdf","url_for_landing_page":"https://doi.org/10.1093/infdis/jiaf608"}}},"created_at":"2026-01-08T08:12:02.165Z","updated_at":"2026-01-14T18:30:49.575Z","tags":[{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"sample_size","value":"n=97","value_numeric":97},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"study_design","value":"Diagnostic Accuracy Study","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"warning","value":"Assay is Research Use Only and not cleared for clinical use.","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"warning","value":"Clinical results are limited to plasma specimens; generalizability to other matrices is unclear.","value_numeric":null},{"paper_doi":"10.1093/infdis/jiaf608","tag_type":"warning","value":"Study design mixes analytical validation with a small retrospective diagnostic accuracy study.","value_numeric":null}],"summaries":{"what_studied":"Development and analytical characterization of a 15-minute qualitative HCV RNA point-of-care test on the DASH Rapid PCR system, including dynamic range, limit of detection, specificity, and genotype coverage. A small, independent preliminary clinical validation used 97 retrospectively collected plasma specimens compared with commercial platforms.","key_result":"The RUO DASH HCV assay detected HCV genotypes 1–6 with a limit of detection of 200 IU/mL using 100 μL input, and in 97 plasma specimens showed 100% positive percent agreement and 100% negative percent agreement versus commercial platforms.","limitations":"Preliminary clinical validation was small (n=97) and used retrospectively collected plasma specimens; the assay is RUO and not yet validated for clinical use.","practice_takeaway":"A 15-minute RUO point-of-care HCV RNA assay showed perfect agreement with commercial platforms in a small study and an LOD of 200 IU/mL; it is promising for same-day diagnosis but requires broader prospective validation before clinical adoption."}},{"doi":"10.1016/j.cgh.2025.11.026","pmid":"41325893","title":"Mental health diseases are associated with active hepatitis C and partly drive HCC trends in Veterans","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2025-12-02T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2025.11.026","source_score":27,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-01","doi":"10.1016/j.cgh.2025.11.026","days":"7","issn":"1542-3565","rank":"2","field":"Clinical Medicine","score":"27","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1016/j.cgh.2025.11.026","title":"Mental health diseases are associated with active hepatitis C and partly drive HCC trends in Veterans.","journal":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","methods":"","results":"We identified 221,721 Veterans, 7% (n=15,710) of whom developed HCC. AUD/SUD was the most prevalent MHD (n=44,140; 19.6%). AUD (6.74%) was the most common individual MHD, with large overlaps between MHD. DAAs improved but did not eliminate the risk of HCC in Veterans (adj.HR=1.32, 95%CI 1.26-1.38 vs. adj.HR=1.59, 95%CI1.89-2.14). AUD/SUD was a significant risk for HCC in the pre-DAA era (adj.HR=1.42, 95%CI1.28-1.59). In the post-DAA era, AUD/SUD significantly interacted with HCV (adj.HR=1.98, 95%CI1.54-2.55).","abstract":"$32","keywords":["Hepatocellular carcinoma","hepatitis C","mental health diseases"],"pubmed_id":"41325893","conclusions":"In a large cohort of Veterans with cirrhosis, any MHD significantly increased incident HCC risk and associated with active HCV, even in the post-DAA era, with AUD and ALD having the largest effects. Multidisciplinary management of vulnerable, at-risk Veterans is needed to mitigate the risk of HCC.","publication_date":"2025-12-02T00:00:00"},"crossref":{"DOI":"10.1016/j.cgh.2025.11.026","URL":"https://doi.org/10.1016/j.cgh.2025.11.026","ISSN":["1542-3565"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S1542356525010110?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S1542356525010110?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Mental health diseases are associated with active hepatitis C and partly drive HCC trends in Veterans"],"author":[{"given":"Nguyen V.","family":"Pham","sequence":"first","affiliation":[]},{"given":"Rajat","family":"Singh","sequence":"additional","affiliation":[]},{"given":"Mei","family":"Leng","sequence":"additional","affiliation":[]},{"given":"Steven-Huy B.","family":"Han","sequence":"additional","affiliation":[]},{"given":"Folasade P.","family":"May","sequence":"additional","affiliation":[]},{"given":"Jasleen","family":"Singh","sequence":"additional","affiliation":[]},{"given":"Jihane N.","family":"Benhammou","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100000738","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,11]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2025-11-29T16:04:47Z","timestamp":1764432287000,"date-parts":[[2025,11,29]]},"indexed":{"date-time":"2025-11-30T22:36:25Z","timestamp":1764542185792,"date-parts":[[2025,11,30]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S1542356525010110"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Mental health diseases are associated with active hepatitis C and partly drive HCC trends in Veterans"},{"name":"journaltitle","label":"Journal Title","value":"Clinical Gastroenterology and Hepatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.cgh.2025.11.026"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 by the AGA Institute"}],"deposited":{"date-time":"2025-11-30T22:29:32Z","timestamp":1764541772000,"date-parts":[[2025,11,30]]},"issn-type":[{"type":"print","value":"1542-3565"}],"published":{"date-parts":[[2025,11]]},"publisher":"Elsevier BV","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S1542356525010110"],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,11]]},"reference-count":0,"published-online":null,"references-count":0,"short-container-title":["Clinical Gastroenterology and Hepatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.cgh.2025.11.026","is_oa":false,"title":"Mental health diseases are associated with active hepatitis C and partly drive HCC trends in Veterans","updated":"2025-12-01T01:08:31+00:00","published_date":"2025-11-01","best_oa_location":null}},"created_at":"2025-12-08T12:24:58.509Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"condition","value":"Alcohol Use Disorder","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"condition","value":"Cirrhosis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"condition","value":"Hepatitis C","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"sample_size","value":"n=221,721","value_numeric":221721},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"study_design","value":"Cohort","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"warning","value":"Design classification is based on the abstract and appears to be a retrospective cohort.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"warning","value":"One confidence interval appears incompatible with its point estimate (aHR 1.59 with 95% CI 1.89–2.14), suggesting a possible typographical error in the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2025.11.026","tag_type":"warning","value":"The abstract reports “Cox logistic regression,” which may be a labeling error for Cox proportional hazards modeling.","value_numeric":null}],"summaries":{"what_studied":"A retrospective cohort of Veterans with cirrhosis (2000–2021) examined whether mental health diseases (AUD/SUD and non‑AUD/SUD diagnoses), rurality, and HCV status (pre‑ vs post‑DAA eras) were associated with incident HCC using multivariable Cox regression.","key_result":"Among 221,721 Veterans, 7% (15,710) developed HCC. AUD/SUD was prevalent (44,140; 19.6%) and associated with higher HCC risk in the pre‑DAA era (adjusted HR 1.42, 95% CI 1.28–1.59), and in the post‑DAA era AUD/SUD significantly interacted with HCV (adjusted HR 1.98, 95% CI 1.54–2.55); DAAs improved but did not eliminate HCC risk (adjusted HR 1.32, 95% CI 1.26–1.38 vs 1.59, 95% CI 1.89–2.14).","practice_takeaway":"In cirrhotic Veterans, mental health conditions—especially AUD/SUD—mark higher HCC risk even after DAAs; integrate mental health and addiction care into cirrhosis management to mitigate risk."}}],"initialOffset":9,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Hepatitis C"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Hepatitis C"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Hepatitis C"}}}]]

Papers